Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib plus ramucirumab versus erlotinib plus placebo in untreated EGFR-mutant metastatic NSCLC
jRCT2080222887Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2015
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Ramucirumab + erlotinib with Placebo + erlotinib (2 arms). Started Jun 2015; status: completed.
02
Drugs
ramucirumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080222887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222887.